REFERENCES
- Ciechanover A, Schwartz AL, Lodish HE The asialoglycopro-tein receptor internalizes and recycles independently of the transferrin and insulin receptors. Cell 1983; 32: 267–75.
- Poralla T, Treichel U, Lohr H, et al. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991; 3: 215–22.
- Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974; 41: 99–128.
- OGT 719 Investigators' Brochure, Abingdon, Oxford, UK: GlycoSciences; 1998.
- Rohlff C, Holt G, Trepel C. Enhanced liver specific activity of glycan-conjugated 5-FU for the treatment of human hepato-cellular carcinoma. Proc Am Assoc Cancer Res 1997; 38: 698 (Abstract).
- Rohlff C, Watson SA, Morris TM, et al. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C17OHM2. Cancer Res 1999; 59: 1268–72.
- Sharma RA, Eatock MM, Twelves CJ, et al. Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Che-mother Pharmacol 2001; 48: 197–201.
- MacMillan WE, Wolberg WH, Welling PG. Pharmacokinetics of fluorouracil in humans. Cancer Res 1978; 38: 3479–82.
- Floyd RA, Hornbeck CL, Byfield J, et al. Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. Drug Intell Clin Pharm 1982; 16: 665–7.
- Christophidis N, Vajda JE, Lucas I. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 1978; 3: 330–6.
- Fleming RA, Milano GA, Etienne MC, et al. No effect of dose, hepatic function or nutritional status on 5-FU clearance following continuous (5-days), 5-FU infusion. Br J Cancer 1992; 66: 668–72.
- Tsukuma H, Hiyama T, Tanaka S, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47–53.
- Johnson PH, Williams R. Cirrhosis and aetiology of hepato-cellular carcinoma. J Hepatol 1987; 4: 140–7.
- Falkson G, Ryan LM, Johnson LA, et al. A randomised study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60: 2141–5.
- Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987; 71: 1213–9.
- Leung TWT, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Research 1999; 5: 1676–81.
- WHO Handbook for reporting results of cancer treatment. World Health Organisation, Geneva, WHO offset publication No. 48, 1996.
- Trere D, Fiume L, Badiali DL, et al. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. B J Cancer 1999; 81: 404–8.
- Hyodo I, Mizuno M, Yamada G, et al. Distribution of asialoglycoprotein receptor in human hepatocellular carci-noma. Liver 1993; 113: 80–5.